Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Check out this video on ARYC about half way down page!
https://allergycarecenters.org/
Huge news on ARYC! Arrayit production team commences $27.9 million microarray manufacturing run to build inventory for our clinical network offering physician-ordered allergy testing services as personalized medicine tools to improve allergy patient healthcare and wellness arrayit.com/Services/servi…
Hi PTC! I'm doing good. How you been?
STAU if you can get the CEO to play ball.
Anymore tips of undervalued plays? WINMQ and ARYC have turned out to be JUNK.
Congratulations to the longs holding ARYC!
Didnt get any $WINMQ .05's yet but Im Not UNDERWATER like the .31-.43's are.
Boy oh boy those .43's were a lousy call
Thank you for the update. $1.42 Billion last quarter and trading this low? Yes, please
Breakout!?, $WINMQ more like a Breakdown. This is going LOWER
PennyTradersClub has Windstream Holdings https://www.windstream.com/about/windstream-information/company-overview on watch for a massive breakout from the current share price of .37/share. We believe that this company is incredibly undervalued at any share price under $20/share. We see the following from the last Quartly report (10Q):
Total revenue and sales:
$1.420 Billion
[$5.6 Billion annualized]
Total cost of sales:
$1.345 Billion
[$5.3 Billion annualized]
Net income:
$ 41.3 million
[$165 million annualized]
Yes, you read that correctly: Net income of $41.3 million ... last quarter alone! $1.42 Billion in sales ... last quarter alone!
Again, we believe that Windstream is incredibly undervalued at this level (share price has a historical high of $112/share)
A few points:
1. Shareholders and share structure remains intact.
2. There will be no change in share structure whatsoever.
3. This is a voluntary restructuring, not a Chapter 7.
4. Insiders are buying https://www.sec.gov/Archives/edgar/data/1282266/000122520818008610/xslF345X03/doc4.xm
Buying at this level should be an opportunity to build massive gains. Please review the links below:
https://investor.windstream.com/news/news-details/2019/Windstream-Holdings-Inc-Files-for-Voluntary-Reorganization-Under-Chapter-11-of-the-US-Bankruptcy-Code-Following-Judge-Furmans-Decision/default.aspx
https://en.wikipedia.org/wiki/Chapter_11,_Title_11,_United_States_Code
https://www.sec.gov/Archives/edgar/data/1282266/000128226618000052/a2018093010q.htm
https://www.windstream.com/about/windstream-information/company-overview
http://news.windstream.com/news-releases/news-release-details/windstream-holdings-inc-files-voluntary-reorganization-under
https://www.sec.gov/Archives/edgar/data/1282266/000128226618000033/a2017form11-k.htm
https://www.instagram.com/windstream_talent
?$WIN Windstream receives approval of motions to support normal business operations https://t.co/ujfvKIJzQg pic.twitter.com/ZS5mX1fBzi
— Windstream (@Windstream) February 26, 2019
The Q hits Wednesday, EVERY media rag covering the last BK-Q will be on this like vultures on road kill.
Todays .37 cents may see single digits by FRYday
Im looking for .05 cents
The Q hits Wednesday, EVERY media rag covering the last BK-Q will be on this like vultures on road kill.
Todays .37 cents may see single digits by FRYday
Im looking for .05 cents
I'll place a order for .05 cents
.20 puts Market Cap for WIN at $9 Million. As nice as that would be to load up on a couple million shares there, I don’t see it getting that low. If it does, they will be devoured IMO
I dont think the market is done taking WIN down. Once the Q hits Wednesday that'll trigger more eyes and the tutes will definatley take notice.
Fundamentally WIN is a solid company, so whenever this controversy subsides, they should regain past numbers.
That would be explosive for anyone who bought in under .20 cents
PennyTradersClub has Windstream Holdings https://www.windstream.com/about/windstream-information/company-overview on watch for a massive breakout from the current share price of .37/share. We believe that this company is incredibly undervalued at any share price under $20/share. We see the following from the last Quartly report (10Q):
Total revenue and sales:
$1.420 Billion
[$5.6 Billion annualized]
Total cost of sales:
$1.345 Billion
[$5.3 Billion annualized]
Net income:
$ 41.3 million
[$165 million annualized]
Yes, you read that correctly: Net income of $41.3 million ... last quarter alone! $1.42 Billion in sales ... last quarter alone!
Again, we believe that Windstream is incredibly undervalued at this level (share price has a historical high of $112/share)
A few points:
1. Shareholders and share structure remains intact.
2. There will be no change in share structure whatsoever.
3. This is a voluntary restructuring, not a Chapter 7.
4. Insiders are buying https://www.sec.gov/Archives/edgar/data/1282266/000122520818008610/xslF345X03/doc4.xm
Buying at this level should be an opportunity to build massive gains. Please review the links below:
https://investor.windstream.com/news/news-details/2019/Windstream-Holdings-Inc-Files-for-Voluntary-Reorganization-Under-Chapter-11-of-the-US-Bankruptcy-Code-Following-Judge-Furmans-Decision/default.aspx
https://en.wikipedia.org/wiki/Chapter_11,_Title_11,_United_States_Code
https://www.sec.gov/Archives/edgar/data/1282266/000128226618000052/a2018093010q.htm
https://www.windstream.com/about/windstream-information/company-overview
http://news.windstream.com/news-releases/news-release-details/windstream-holdings-inc-files-voluntary-reorganization-under
https://www.sec.gov/Archives/edgar/data/1282266/000128226618000033/a2017form11-k.htm
https://www.instagram.com/windstream_talent
$WIN Windstream receives approval of motions to support normal business operations https://t.co/ujfvKIJzQg pic.twitter.com/ZS5mX1fBzi
— Windstream (@Windstream) February 26, 2019
View System, Inc (VSYM) a concealed weapons detection & security company.
ViewScan Original:
Locates and Visually Indicates Threat Objects
Adjustable Audible Alarm
Reduces False Alarms
Faster Throughput than Conventional Metal Detectors
Safe for Medical Devices such as Pacemakers
Easily Movable
Easy to use Intuitive Graphical User
Interface (GUI)
Image and Data Archiving
Optional 4-Hour Battery (sold separately)
Quickly Prints Evidence (printer sold separately)
Seamlessly Integrates with View’s Positive
ID Management System (sold separately)
Weighs only 56 lbs (75lbs shipping weight)
Camera can be mounted to unit as shown (instead of a separate camera which must be installed across from the unit on the walls of the facility)
http://viewsystems.com/VS/products/access-control-systems
Now in addition to all that...
The new superior “ViewScan II” will be the “Swiss Army Knife” of walk through detectors incorporating a multiple of sensing devices.
Facial recognition, airborne chemicals, radiation detection, “sniffer” technologies and record keeping of individuals coming and going are just some of the comprehensive capabilities. Self contained, battery operated, portable with wireless communication to a central network makes this THE security detector of choice. The “ViewScan II” is the first such “smart” portal to enter the market. View is readying this superior product to enter the security market in 2019.
https://finance.yahoo.com/news/view-systems-inc-announces-product-144058653.html
The CEO, Gunther Than, can confirm that things are moving along nicely for the company especially with this new superior product that’s getting ready to enter the market in the first quarter of 2019.
Stay tuned for additional updates & press releases!
The new superior “ViewScan II” is a new product and is different from the old product, which used the same name in the past (over a decade ago). I know that some folks on the board questioned the similar name, but a simple glance of this new product will give you the impression that this is definitely the future of security technology.
Here’s a good email to confirm the above information or simply to email the CEO requesting additional information...
gthan@viewsystems.com
“ViewScan” product demo:
http://viewsystems.com/VS/video-demos
Key points as to why the “ViewScan” technology is superior from the competition:
Passive Technology
* It does not generate or emit any radiation what so ever.
* Being safe for everyone who walks through it.
Having a picture of everyone who walks through it.
Laptop controlled
* Being able to look at the screen & pin point where the items are visually.
Network Connectivity
* Being able to connect multiple view scans together as well as tie to your existing surveillance system.
$VSYM pink current information:
https://www.otcmarkets.com/stock/VSYM/news
Big partnerships in the works... View Systems, Inc has ties to PRG Potomac River Group who does a lot of business with several government agencies.
http://www.prgusa.net/about-us/
View Systems’ products are currently installed in the United States in schools, correctional facilities, law enforcement facilities, and a variety of federal agencies and have been or are being used by the SEC, IRS and Secret Service. The original View Scan has been used by the national affiliations such as NFL’s Super Bowl, MLB’s All Star Games and National Democratic Committee conventions.
NEW PR...Arrayit Corporation Announces In-Network Allergy Testing Services Contract with a Top Five Commercial Healthcare Benefits Company http://bit.ly/2GIkriW
Welcome Kaboom!
Final Alert update on SHLDQ (2-2-19) and expected 8K on Tuesday:
Hope you are having a great New Year and the Market is treating you well ?? a quick update on Sears/Kmart [OTCBB: SHLDQ] and the updated $5.2 Billion accepted buyout (see link) received last week and pending acceptance on Monday:
This stock [OTC: SHLDQ] is both Sears and Kmart. Please review the links at the bottom from recent 8Ks. There has been an active and confirmed Short Attack that brought the SHLDQ from $140+/share down to under .40/share and volatility brought it to where it is now (.54/share) but with a reversal and last weeks announcement of a buyout for $5.2 Billion and news coming next week, we believe that SHLDQ will head back over $47/share.
There are now over 600 Kmart and Sears stores in operation in the United States with over 50,000 employees. Sears and Kmart are currently undergoing restructuring under Chapter 11 to rebuild, keep the 425 most profitable stores, and with assets of over $3 billion, this SHLDQ market cap of $58 million is unbeatable by any other pennystock.
A few facts:
SHLDQ has Outstanding Shares of less than 109 million
Float of less than 30 million shares
Market Cap of $58 million
SHLDQ insiders own over 70% of the 109 million OS
With chapter 11 restructuring, we expect that the over 600 stores nationwide will return SHLDQ back to $47+ per share.
https://www.reuters.com/article/us-sears-pensions/u-s-agency-seeks-approval-to-take-over-sears-pensions-idUSKCN1PQ5US?il=0
https://www.latimes.com/business/la-fi-sears-20190109-story.html
https://www.cnbc.com/2019/01/09/eddie-lampert-reportedly-submits-revised-bid-of-roughly-5-billion-to-save-sears-from-liquidation.html
https://finance.yahoo.com/news/lampert-said-ready-higher-bid-165137897.html
https://www.cnbc.com/2019/01/08/chairman-eddie-lampert-to-get-another-chance-to-save-sears-sources-say.html
$ARYC clinical sales team announces enrollment of Kaiser Permanente in our Patient Data Solutions allergy testing portal providing on-line test kits, test reports and immunotherapy options for allergy and asthma doctors in one of the nation's top HMOs patientdatasolutions.com/signup/rs4884/
Just a reminder please continue to hold ARYC you won’t regret it! We are expecting NASDAQ in 2019 huge opportunity will create generation wealth for all of us!
Congratulations to those that got into CBBT! Nice profits!
VNUE is a new pick! Entry .0044 area we could see copper easily ~105M float
PTCers it’s a good time to get back in SHLDQ coming out of BK!
$INTV follows Crypto currency, Just completed re-AUDITING their 2017 2018 10 K's due to Accountants PCAOB reprimand, awaiting Q1 2019 should be filed this coming week.
Definately one for your watchlist, dont wait too long in taking a potition. When BTC turns around INTV follows.
PTCers keep an eye on SHLDQ on Monday we could see the start to a nice run!
Patent & NIH clinical trials for Arrayit Corp (ARYC) major microarray product line pending FDA approval.
Spiriplex like AllergyPro is one of Arrayit’s marketing partners.
Spiriplex Patent: Method and device for allergy testing and treatment.
https://patents.google.com/patent/WO2016179402A1/en
https://www.freshpatents.com/-dt20161110ptan20160327567.php
Methods of applying proteins to surfaces to form arrays are well known. The immobilization may be covalent or noncovalent, via a linker moiety, or tethering to an immobilized moiety. These methods are well known in the field of solid phase synthesis and micro-arrays, for example as described in Beier et al., Nucleic Acids Res. 27:1970-1-977 (1999), and U.S. Pat. No. 6,101,946 to Martinsky. Examples include binding moieties for attaching proteinaceous molecules to a solid support include streptavidin or avidin/biotin linkages, carbamate linkages, ester linkages, amide, thiolester, (N)-functionalized thiourea, functionalized maleimide, amino, disulfide, amide, hydrazone linkages, and among others. Furthermore, a number of companies offer commercial services for preparing protein arrays, for example Arrayit Corporation (Sunnyvale, Calif.). Preferably, the source of the proteins is an extract of the allergen source, such as those available from GREER® Allergy Immunotherapy (Lenoir, N.C.). Preferably, the extract of the allergen source is standardized.
Aspects of the inventions described herein have been described on the website of ARRAYIT® Corporation (arrayit.com) and links thereon. All such disclosures were made by another who obtained the subject matter disclosed directly or indirectly from the inventor of the present application.
1-2-18: Arrayit completes site visit and laboratory tour with a key business-to-business B2B partner and regulatory consultant regarding submission of a proprietary microarray product line to the United States Food and Drug Administration for FDA clearance https://www.fda.gov
Allergenex/Spiriplex:
http://spiriplex.com/
Spiriplex/AllergyPro
http://allergypro.us/wp-content/uploads/2016/09/ICD-9-to-ICD-10-Codes.pdf
1-3-18 Arrayit advanced microarray technology to be incorporated into a clinical trial by a major pharmaceutical giant in a development that could significantly increase revenues and earnings in 2018 arrayit.com/Products/products.html
United Allergy Services sponsoring Spiriplex.
https://clinicaltrials.gov/ct2/show/NCT03514303
National Institutes of Health: Arrayit submits capabilities statement for major microarray services contract with National Institutes of Health NIH nih.gov
3-21-18: Arrayit sales and marketing team receives $1,050,000 genomics and proteomics pre-solicitation announcement from top government agency National Institutes of Health NIH headquartered in Bethesda Maryland USA and operating with a $31.3 billion annual budget https://www.nih.gov
Arrayit government contracts team reports $440,000 sample testing solicitation from the world leader Department of Health and Human Services National Cancer Institute NCI headquartered in Bethesda Maryland USA and supported by a $5.4 billion annual budget (link: https://www.cancer.gov) cancer.gov
NIH first posted May 2, 2018
* Note: Arrayit Corp (ARYC) began releasing press releases once again in May 2018.
http://arrayit.com/Arrayit_Corporation_ARYC_Corpo/Microarray_Media_-_Press/microarray_media_-_press.html
7-16-2018: Arrayit Corporation Reports Clinical Instrumentation Sale to the United States Food and Drug Administration
http://arrayit.com/Arrayit_Corporation_ARYC_Corpo/Microarray_Media_-_Press/Arrayit_Corporation_Reports_Cl/arrayit_corporation_reports_clinical_instrumentation_sale_to_the.html
9-24-2018: Arrayit Corporation Ships Clinical Instrumentation and Software to the United States Food and Drug Administration
http://arrayit.com/Arrayit_Corporation_ARYC_Corpo/Microarray_Media_-_Press/Arrayit_Corporation_Ships_Clin/arrayit_corporation_ships_clinical_instrumentation_and_software_.html
https://www.fpds.gov/ezsearch/fpdsportal?q=arrayit&s=FPDSNG.COM&templateN=&&templateName=1.5.1&indexName=awardfull
Arrayit Corp (ARYC) Has firmed several immunotherapy partnerships & several clinics have recently enrolled in their Patient Data Solutions allergy testing portal, therefore, one could also easily form the opinion that we are in phase III of the clinical trials & about to enter the final step
A Phase III trial gathers more information about safety and effectiveness, studying different populations and different dosages, using the drug in combination with other drugs. The number of subjects usually ranges from several hundred to about 3,000 people. If the FDA agrees that the trial results are positive, it will approve the experimental drug or device.
A Phase IV trial for drugs or devices takes place after the FDA approves their use. A device or drug's effectiveness and safety are monitored in large, diverse populations. Sometimes, the side effects of a drug may not become clear until more people have taken it over a longer period of time.
https://www.nia.nih.gov/health/what-are-clinical-trials-and-studies
Further, below are the Medicare Coverage policies along with Arrayit Corp (ARYC) press release a few days before entering the NIH clinical trials.
Effective September 19, 2000, clinical trials that are deemed to be automatically qualified are:
1. Trials funded by NIH, CDC, AHRQ, CMS, DOD, and VA;
2. Trials supported by centers or cooperative groups that are funded by the NIH,
CDC, AHRQ, CMS, DOD and VA;
3. Trials conducted under an investigational new drug application (IND) reviewed
by the FDA; and
4. Drug trials that are exempt from having an IND under 21 CFR 312.2(b)(1) will be
deemed automatically qualified until the qualifying criteria are developed and the certification process is in place. At that time the principal investigators of these trials must certify that the trials meet the qualifying criteria in order to maintain
Medicare coverage of routine costs. This certification process will only affect the future status of the trial and will not be used to retroactively change the earlier deemed status.
https://www.cms.gov/Medicare/Coverage/ClinicalTrialPolicies/downloads/finalnationalcoverage.pdf
Arrayit Corporation Announces New Clinical Licensure from the Centers for Medicare and Medicaid Services
Sunnyvale, May 09, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces receipt of a new clinical licensure from the Centers for Medicare and Medicaid Services (CMS), which oversees the Clinical Laboratory Improvement Amendments (CLIA) Program. Arrayit’s new CLIA license, issued in conjunction with the Department of Health and Human Services (HHS) and the California Department of Public Health (CDPH), provides certification for its Silicon Valley clinical laboratory.
http://arrayit.com/Arrayit_Corporation_ARYC_Corpo/Microarray_Media_-_Press/Arrayit_Corporation_Announces_/arrayit_corporation_announces_new_clinical_licensure_from_the_ce.html
?Congratulations to those that got in $SHLDQ we received good news!?? Watch for gap in the morning!?
$ARYC Microarray product line has been submitted to the FDA & now pending approval.
1-2-18: Arrayit completes site visit and laboratory tour with a key business-to-business B2B partner and regulatory consultant regarding submission of a proprietary microarray product line to the United States Food and Drug Administration for FDA clearance https://www.fda.gov
Allergenex/Spiriplex:
Microarray finger stick allergy testing clinical trials...
https://clinicaltrials.gov/ct2/show/NCT03514303
Start date of clinical trials was May2018.
Completion date of clinical trials is February 2019.
Sponsor United Allergy Services located in San Antonio Texas.
https://www.unitedallergyservices.com/united-allergy-services-about/
https://allergyfreesolutions.com/item/microarraytechnology/
http://spiriplex.com/allergies/
Arrayit business development team reports revenues and earnings expansion opportunity with a leading allergy testing clinic headquartered in San Antonio Texas USA and serving the massive health and wellness allergy and asthma testing services markets (link: http://arrayit.com/Clinical/clinical.html) arrayit.com/Clinical/clini…
Arrayit business development team reports revenues and earnings expansion opportunity with a leading allergy testing clinic headquartered in San Antonio Texas USA and serving the massive health and wellness allergy and asthma testing services markets https://t.co/TRfj3lWfRd pic.twitter.com/CZdPimKrtf
— Arrayit Corporation (@arrayit) January 3, 2019
ARYC
The CEO Letter to Shareholders summarizes company accomplishments during a dynamic 2018 fiscal year and outlines ambitious goals for 2019.
http://arrayit.com/Arrayit_Corporation_ARYC_Corpo/Microarray_Media_-_Press/Arrayit_Corporation_Announces_/arrayit_corporation_announces_chief_executive_officer_letter_to_.html
http://www.arrayit.com/confidential/Letter-to-Arrayit-Shareholders.pdf
Recent email response:
“The financials are right on schedule, following the industry standard 8-12 weeks per fiscal year. Based on the excellent progress, we decided to file all of the 10-Ks and 10-Qs at the same time, rather than one fiscal year at a time. The total time to complete the audit is the same as always. Our web team will update the web to reflect the CEO Letter to Shareholders' timeline of filing in the first quarter of 2019. Thanks, Mark”
Financials are imminent...
February 14, 2019 deadline for the 2018 Q3 financial statements for Delinquent Filers...
https://www.skadden.com/-/media/files/publications/2018/12/2018yearendchecklist.pdf?la=en
ARYC stock is about to go parabolic IMO :)
PTCers $FTEG ~218 million float! CBD pet industry and ECO cleaning Products and future merger coming up! Run up into pennies possible in the near future!
ARYC
AllergyPro is the only company to use the same proteins for blood testing, scratch testing and immunotherapy in the world.
https://s3.amazonaws.com/bbemail/PROD/ulib/p5d1n/docs/73d0e7a8-72f3-5203-445b-dfea5f12a989/HMAllergyProSales11.12.16.pdf
LabPharm subsidiary Allergy Labs of America...
For over 10 years, Allergy Labs of America has specialized specifically in the Allergy Testing and Treatment services. ALA is an Ancillary service company offered from our parent company LabPharm LLC.
LabPharm has over 50,000 physicians currently utilizing services offered. ALA Works with a vast network of these clinics to provide a gold standard of healthcare to patients, promote higher education, and innovation within our field.
Our Goal is to provide patients a more effective, safe, and healthy alternative to help your patients end their suffering from allergies. We are passionate about this goal, which is clearly seen in the quality of the service we provide to patients, and staff alike.
http://www.allergylabsofamerica.com/about-us/
$NSPX .006 CAN IT RUN TO OVER $3?
$NSPX .006?! WAS 55 CENTS. CANCER PATENT GRANTED NOT PR'ed. UNKNOWN. If you ever heard about $NSPX chances are you heard it from ME.
https://patents.justia.com/assignee/inspyr-therapeutics-inc
$NSPX HUGE Merger. NOT PR'D????
https://globenewswire.com/news-release/2017/09/13/1120305/0/en/Inspyr-Therapeutics-and-Lewis-and-Clark-Pharmaceuticals-Complete-Merger.html
Only 9 MILLION shares outstanding?
YOU guys KNOW how pharma stocks run from subs to $$$ ranges. $NSPX has a patent signed a $100 million private financing already received 25 million. Its A lotto for me but I like her. You see on the L2 after .02 is $200, THIN. Only reason its down at this mouth watering price is because it is VERY UNKNOWN. Won't be unknown for long
This is a little sloppy write up. Just little items I connected together. Trying to simplify the DD.
$NSPX Secures Patent on Methods of Producing Cancer Targeting
Inspyr Therapeutics Secures Patent on Methods of Producing Cancer Targeting CompoundsPharmaceutical | Tue 19 Dec 2017Alexandria, Dec. 19 -- Inspyr Therapeutics has secured a patent on methods of producing cancer targeting compounds. Lynch John K, Hutchison Jeff, #$%$ Xiong and Kunnen Kevin developed the invention. The patent application number is 15/232,599. The International Patent Classification codes are C07D 307/93 (20060101), C07C 227/16 (2..
"INSPYR THERAPEUTICS AND LEWIS AND CLARK PHARMACEUTICALS MERGE"
"Lewis & Clark Pharma: We have deep expertise in the synthesis, analysis, and early stage development of adenosine receptor-based compounds, with a focus on A2A and A2B antagonists, and A2A agonists. Our proprietary compounds are highly potent and selective, and – most importantly, have molecular properties that enable enhanced distribution in tissue and penetration of human skin – and the opportunity for novel therapies that could address a broad range of large, chronic, underserved diseases:
A2A/A2B antagonists for a range of tumors, as a mono- or combination therapy, including:
Solid tumors, e.g., breast, colorectal, melanoma, lung, prostate, bladder
Hematological malignancies, e.g., multiple myelomas, acute lymphocyte leukemia"
From the annual report from fiscal year ending December 31, 2016: Our major focus for the next twelve to eighteen months is the (i) development of a clinical protocol for and enrollment into a dose optimization trial of single-agent mipsagargin followed by a clinical trial in patients with advanced HCC, (ii) completion of the non-clinical study of mipsagargin in combination with Nexavar® in liver tumor models (iii) development of a Phase 1b clinical protocol of mipsagargin in combination with Nexavar® in patients with Nexavar® naïve HCC in anticipation of positive non-clinical data, (iv) completion of a nonclinical study of mipsagargin in combination with paclitaxel and in combination with DC101 (Cyramza surrogate antibody) in gastric cancer tumor models, (v) ongoing business development discussions with potential development partners, (vi) evaluation of mipsagargin (single agent and in combination with standard of care) in nonclinical models of other solid tumor types that express PSMA, (vii) evaluate our PSMA-peptide prodrug technology with new linkers and new payloads in non-clinical models, and (viii) explore collaborations utilizing mipsagargin in new, non-clinical solid tumor models with leading researchers in the oncology field.
Proceeds will be used to advance Inspyr’s clinical development plans and provide for working capital needs. The Company’s entry into the Milost Equity Subscription Agreement Financing Facility (MESA) and the initial tranche of funding is subject to required approvals, final documentation, and customary closing conditions.
“We are pleased to have reached an agreement on the key investment terms, the first step in securing a solid foundation of capital for Inspyr for the next several years,” said Peter Grebow, Ph.D., Chairman of Inspyr Therapeutics.
“We are pleased to be a financial partner to Inspyr and look forward to closing the transaction promptly,” said Egerton Forster, Milost Global Inc. Co-found
NSPX RECENTLY SECURED
100M in financing from private equity firm, the needle is moving in the right direction.
"Well...I see that they have started a couple trials involving treatment with sorafenib with mipsigargin as an adjuvant therapy.
Hmmmmmmmmmmmmmmmmm...they say they are looking for a synergistic effect from the combo. The non pre clinical trial will be used on folks with advanced HCC, so they are looking for arresting progression of the disease. Mipsigargin was a lot better at arresting progression than sorafenib's 2 months. Perhaps together they can arrest progression for a year or more. I suspect that even with progression arrested, many folks will die as a result of the damage the cancer has already caused.
Hey...the company is moving forward again. Cheers for the new year!!!"
Can $NSPX run over $3? Its a cancer pharma stock with patents. 1 succesful trial away from $100+ imo. You know how these pharmas go. Hit or miss.
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
Report TOS
Sunnyvale, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces an allergy testing agreement with Northern California healthcare leader Sutter Health. The company is providing its proprietary microarray-based finger stick allergy testing services to Sutter Health via doctors in the Sutter Health-affiliated Palo Alto Medical Foundation. Sutter Health, one of the nation’s largest healthcare networks, is headquartered in Sacramento California and has 50,000 employees including 12,000 physicians and 14,000 nurses serving 3 million Northern California patients. Sutter Health draws 19% of its revenue from the California Medical Assistance Program (Medi-Cal) and reports total patient service revenues of $12,000,000,000 ($12 billion) annually.
ARYC
Arrayit on-line company Store sales exceed $55.5 million all-time on 226,285 microarray products and services sold
twitter.com/arrayit
Arrayit Corporation on Facebook
Please DD and research what's about to happen here.
http://www.arrayit.com/
A list of Arrayit Corporation patents:
https://t.co/EMXlE743rz
A link to their products:
http://www.arrayit.com/Products/products.html
Get in now my friends :)
$ETII Just a few things we have:
1. CBD Energy Shots
2. BCAA+CBD Post Workout Powder
3. CBD Brownies
4. CBD+Hemp Protein Powder
5. CBD Oil cartridges
6. CBD Micro Dose Spray
7. CBD Gummies
8. CBD Capsules
9. CBD Syrup
10. CBD Oil for Food/Drinks/Vapes
11. CBD Pet Line ***Coming Soon***
CYBF is a low floater ready to run
For all new shareholders of $ARYC please read:
Website:
http://www.arrayit.com/
Check out their Facebook page: Arrayit Corporation
Follow $ARYC on Twitter @Arrayit
Arrayit completes strategic conference call with $183.9 billion pharmaceutical giant Novartis NYSE:NVS Cambridge MA https://www.novartis.com
Arrayit reports Parkinson's Disease Test PDx™ partnering opportunity with top physician in Molecular Medicine India (link: http://nimhans.ac.in) nimhans.ac.in
Arrayit reports $350,000 microarray services inquiry from leading Veterans Administration Health Care Palo Alto CA paloalto.va.gov
ARYC reports partnership opportunity with $655M healthcare manufacturing leader Quidel Nasdaq:QDEL San Diego Ca
ARYC: $8,000,000+ in sales in 2016
Incredibly undervalued. Please DD
@Arrayit
http://www.arrayit.com/
$24.4 million contract just signed
ARYC also owns 34 million shares of AVDX.
Arrayit's corporate headquarters, located at 927 Thompson Place, Sunnyvale, California, 94085, feature 15,000 square feet of modern industrial space including 45 parking spaces, offices, conference rooms, demonstration laboratories, class 100 cleanrooms, and manufacturing and shipping facilities.
Arrayit new company newsletter to feature our popular microarray-based genotyping services for biomedical research arrayit.com/Services/SNP_G…
Arrayit receives $168,000 letter of credit from top microarray technology and life science distributor in South Asia
(link: http://arrayit.com/Products/products.html)
arrayit.com/Products/produ…
Arrayit receives new financing lead that could generate 6,000 x $100K = $600MM in Arrayit microarray platform sales
http://
arrayit.com
Arrayit reports 1,000 whole blood collection card sale to to research lab in Southern US
http://
arrayit.com/Products/Prote
in_Microarrays/Blood_Card/blood_card.html
…
Arrayit reports $15K microarray sale to top medical Stephenson Cancer Center Oklahoma City
http://
stephensoncancercenter.org
Arrayit Store sales exceed $54 million all-time on 222,269 microarray products and services
http://
shop.arrayit.com
?pic.twitter.com/HbVEPj4bMX?
Arrayit reports $18,500 microarray platform sale life sciences leader ChemBio Moscow Russia
?http://www.?
?chembio.ru?
Arrayit quotes $160,000 microarray platform to molecular diagnostic leader Akonni Biosystems
http://www.
akonni.com
Arrayit production team expands blood card manufacturing to 10,000 units per week to meet microarray research demand
http://
arrayit.com/Products/Prote
in_Microarrays/Blood_Card/blood_card.html
…
Arrayit customers at Axo Science Lyon France use Arrayit microarray platform to ID bladder cancer prevention markers
http://
arrayit.com/Publications/b
ladder-cancer-prevention.pdf
…
Arrayit reports microarray technology sale to top nanotechnology healthcare leader Sonanutech Davis CA
http://
sonanutech.net
Arrayit reports microarray technology sale to world diagnostics leader Ventana Medical Sysytems Roche Tucson AZ
http://www.
ventana.com
Arrayit contact top Wells Fargo analyst Tim Evans explains revenue/earnings synergies in life science & diagnostics
http://
arrayit.com/Wells-Fargo-16
1114.pdf
…
Arrayit ships $35K proprietary microarray platform to leading European distributor Grupo Taper Mem Martins Portugal
http://www.
taper.es
Arrayit reports microarray technology sale to agricultural biotechnology leader Microgaia Biotech Murcia Spain
http://
microgaia.eu
Arrayit reports $10K microarray technology sale to world proteomics leader CDI Laboratories located in Baltimore MD
http://
cdi-lab.com
Arrayit featured in Global DNA Microarray Market Research Report 2016 with top molecular DX companies GE and Cepheid
http://www.
reportsnreports.com/reports/732130
-global-dna-microarray-market-research-report-2016.html
…
Arrayit designs custom microarray technology platform for top wellness testing company located in the European Union
http://
arrayit.com/Products/Micro
array_Platforms/microarray_platforms.html
…
Arrayit customers at the Korea Research Institute use the Arrayit microarray platform to publish biosensors advance
http://
pubs.acs.org/doi/abs/10.102
1/acs.analchem.6b02071
…
Arrayit confirms site visit business development meeting with advanced genomics leader Genomic Vision Bagneux France
http://www.
genomicvision.com
Arrayit SpotBot® Extreme Microarray Spotter newsletter receives 3,265 hits on life sciences tools segment strength
http://
arrayit.com/Products/Micro
arrayers/Microarray_Spotter/microarray_spotter.html
…
Arrayit reports $200,000 microarray platform inquiry from top life sciences leaders AH Diagnostics Aarhus Denmark
http://www.
ahdiagnostics.dk
Arrayit reports $34K microarray instrument sale to top European Union life sciences distributor European Biotech Network Dolembreux Belgium.
Arrayit equity research contact Tim Evans Wells Fargo illustrates 15-quarter strength of venture capital investing in biotechnology sector.
Arrayit signs 3-year $24.4 million patented microarray technology sales and marketing agreement with a leading laboratory services provider.
Arrayit customers from Arizona State use Arrayit microarray technology to publish adult stem cell therapy advance
http://www.
sciencedirect.com/science/articl
e/pii/S1873506115000598
…
Can an antibody microarray made with Arrayit technology replace in-situ hybs in HER2 breast cancer diagnostics?...
?http://?
?fb.me/2Xx9b1Oom?
Arrayit quotes $179,430 microarrays to biomedical leader Progenie Molecular Valencia España
http://www.
progenie-molecular.com
Arrayit quotes $51,680 microarrays to top leader De La Salle University Manila Philippines
http://www.
dlsu.edu.ph
Arrayit quotes $102,240 microarray platform to venture think tank Leading Technology Group
http://www.
leadingtechnology.co
Arrayit quotes $38,485 microarray platform to top Korean distributor Daemyung Science Seoul
http://www.
dm4you.com
Arrayit Corporation ??@arrayit?
Arrayit completes conference call on huge DNA testing opportunity in massive market in India
http://
arrayit.com/Services/SNP_G
enotyping/snp_genotyping.html
…
Arrayit reports DNA testing inquiry from top agency in India. Market penetration of 0.1% would produce $48M revenues
http://
arrayit.com/Services/SNP_G
enotyping/snp_genotyping.html
…
Arrayit Corporation ??@arrayit?
Arrayit quotes $235,000 microarray instruments to top lab University Ottawa Ontario Canada
http://www.
uottawa.ca
Arrayit reports microarray sale to advanced technology leaders Waki Company Tokyo Japan
http://
waki-bg.jp
Arrayit reports microarray sale to automated molecular testing leader AutoGenomics Vista CA
?http://www.?
?autogenomics.com?
Arrayit reports microarray sale to life sciences European Biotech Network Dolembreux Belgium
?http://www.?
?euro-bio-net.com?
Arrayit reports microarray sale to top medical researcher at $13.4B endowed MIT Cambridge MA
http://
web.mit.edu
Arrayit expands marketing on $100K+ TissueMax™ Automated and Personal Tissue Microarrayers
Arrayit reports $400,000 microarray instruments inquiry from top European Union distributor
http://
arrayit.com/Products/Micro
arrayers/Microarray_Printers/microarray_printers.html
…
Arrayit invited to appear on Business Television BTV hosted by broadcast partner Bloomberg
?http://www.?
?b-tv.com?
Arrayit $17.7MM OvaDx® spin-off and 6,000 diagnostic test pipeline possibility emphasizes the $17.7MM x 6,000 = $106B ARYC market potential.
Arrayit reports $9K chemical sale in specialty trading subsidiary TeleChem International Inc
http://www.
telecheminternational.com
Arrayit reports $100K microarray inquiry Al Rayyan International Science Center Amman Jordan
https://www.
linkedin.com/in/nader-ghana
yem-3b1306a2?authType=NAME_SEARCH&authToken=ofog&locale=en_US&srchid=2270647621456852532077&srchindex=1&srchtotal=2&trk=vsrp_people_res_photo&trkInfo=VSRPsearchId%3A2270647621456852532077%2CVSRPtargetId%3A365047477%2CVSRPcmpt%3Aprimary%2CVSRPnm%3Atrue%2CauthType%3ANAME_SEARCH
…
ETII is our next play called at .32 expecting $1 or more!
Arrayit manufacturing team completes $1.65 million microarray manufacturing run to build inventory for a major customer commercializing our innovative and non-invasive finger stick microarray allergy test to assist doctors in treating allergy and asthma arrayit.com/Clinical/Aller…
PTCers $NXEN expecting CSE listing any day! So many reasons to buy shares. Check out the DD at OwnTheFloat.com.
ARYC’s RECENT Press Releases and important TWEETS:
5-19-18: Sunnyvale, May 09, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces receipt of a new clinical licensure from the Centers for Medicare and Medicaid Services (CMS), which oversees the Clinical Laboratory Improvement Amendments (CLIA) Program. Arrayit's new CLIA license, issued in conjunction with the Department of Health and Human Services (HHS) and the California Department of Public Health (CDPH), provides certification for its Silicon Valley clinical laboratory.
https://www.marketwatch.com/story/arrayit-corporation-announces-new-clinical-licensure-from-the-centers-for-medicare-and-medicaid-services-2018-05-09?siteid=bigcharts&dist=bigcharts
5-21-18: Arrayit Corporation Scores 100% on Proficiency Testing Conducted by the College of American Pathologists as clinical team aces CAP PT in highly quantitative measurements of IgE using a blinded study protocol. Congratulations to our amazing clinical team!
http://www.globenewswire.com/news-release/2018/05/16/1507332/0/en/Arrayit-Corporation-Scores-100-on-Proficiency-Testing-Conducted-by-the-College-of-American-Pathologists.html
5-30-18: Sunnyvale, CA , May 30, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has achieved the clinical testing accuracy required for reimbursement under Medicare and Medicaid. Accuracy testing, supervised by the College of American Pathologists (CAP), assesses quantitative measurements of the immunoglobulin E (IgE) regulated analyte in the general immunology proficiency testing program. Arrayit’s testing performance included a score of 100% on the SA-2018 proficiency event and constituted successful cumulative performance required by the Centers for Medicare and Medicaid Services (CMS) over a one-year testing period. CMS regulates approximately 260,000 clinical laboratories through the Clinical Laboratory Improvement Amendments (CLIA) program, and proper certification is required to receive Medicare and Medicaid payments.
https://www.marketwatch.com/story/arrayit-corporation-achieves-testing-accuracy-required-for-medicare-and-medicaid-reimbursement-2018-05-30?siteid=bigcharts&dist=bigcharts
6-18-18: June 18, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has engaged a nationwide network of professional sales representatives ("sales reps") to sell and distribute the company's allergy tests across the Continental United States, with focus areas in the Pacific Northwest, West, Southwest, Rocky Mountain, Midwest, Northeast and Southeast regions. The network comprises 1,700 sales professionals including 500 sales reps with specific training in finger stick sampling, blood card collection and microarray technology. This extensive professional network will be used to enroll hospitals, health maintenance organizations (HMOs), doctor's and dentist's offices, health clinics and retail stores into the allergy-testing program.
https://www.marketwatch.com/story/arrayit-corporation-announces-nationwide-allergy-testing-sales-and-distribution-network-2018-06-18?siteid=bigcharts&dist=bigcharts
6-29-18: Arrayit signs capital financing agreement with a top buy-side analyst at a leading corporate intelligence firm headquartered in London UK with offices in New York and providing buy-side intelligence to high net worth retail investors, institutional investors and hedge funds.
https://twitter.com/arrayit/status/1012723616373280768
7-2-18: Sunnyvale, July 02, 2018 (GLOBE NEWSWIRE) -- July 2, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has completed an allergy testing pilot program for one of nation’s largest chains of retail stores. The retailer collected finger stick blood specimens from 126 customers at their in-store clinics, and shipped the blood cards to Arrayit for processing. Arrayit processed the specimens and reported 126 quantitative total immunoglobulin E (IgE) measurements and 15,120 allergen-specific determinations indicative of food and environmental allergies. The test results were reviewed and approved by the retail chain’s Chief Medical Officer.
https://www.marketwatch.com/story/arrayit-corporation-completes-allergy-testing-pilot-program-for-one-of-the-nations-largest-retail-chains-2018-07-02?siteid=bigcharts&dist=bigcharts
7-3-18: Arrayit senior management receives NASDAQ and NYSE up-listing proposal from small and mid-cap consulting experts http://uplisting.com focusing on growth companies seeking to improve and enhance shareholder value by listing on a major stock exchange http://www.uplisting.com
https://twitter.com/arrayit/status/1014187818891935744
7-3-18: Arrayit provides 7/2/18 FDA update: (1) excellent meeting, (2) large attendance by FDA top brass, (3) insightful and instructive, (4) our entire clinical team wishes to thank the agency for their feedback and generosity, and (5) we believe that our test will receive FDA approval.
https://twitter.com/arrayit/status/1014171600051007488
7-8-18: Arrayit web design team updates investor main page and 33 sub-pages including updated information and links regarding Arrayit technology, auditors, biochemistry 101, celebrity spokesperson, CEO, SEC filings, XBRL filings and many other ARYC investor topics http://arrayit.com/Microarray_Investor/microarray_investor.html …
https://twitter.com/arrayit/status/1016023938470576128
7-16-18: July 16, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces the sale of clinical instrumentation to the United States Food and Drug Administration (FDA). Arrayit uses the same clinical instrumentation in its Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the Centers for Medicare and Medicaid Services (CMS) and the State of California Department of Public Health (CDPH). The instrumentation reads and reports test results for the company's allergy and dietary wellness tests and pipeline tests for ovarian cancer and Parkinson's Disease (PD).
https://www.marketwatch.com/press-release/arrayit-corporation-reports-clinical-instrumentation-sale-to-the-united-states-food-and-drug-administration-2018-07-16?siteid=bigcharts&dist=bigcharts
7-25-18: Arrayit senior management completes analyst call with top buy side analyst at the prestigious Alpha Deal Group headquartered in New York NY USA and providing premium independent due diligence for high net-worth retail, instituional and hedge fund customers (link: http://www.alphadealgroup.com) alphadealgroup.com
https://twitter.com/arrayit/status/1022158461302267905
7-30-18: Sunnyvale, July 30, 2018 (GLOBE NEWSWIRE) -- July 30, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, signs allergy testing contracts with a consortium of medical clinics nationwide. The network comprises 178 medical clinics in 29 of the 48 contiguous United States including the Northeast, Southeast, Midwest, South, Southwest, Pacific and Pacific Northwest regions, with single clinics staffing up to 70 physicians. The clinics are using Arrayit allergy testing services to assist physicians in diagnosing and treating allergy and asthma across a wide range of medical specialties and focus areas including anti-aging, back pain and sciatica, chiropractic care, dermatology, digestive health, ear nose and throat (ENT), family medicine, gastroenterology, health and beauty, immunology, integrative medicine, internal medicine, obesity, obstetrics and gynecology (OB-GYN), pain relief, pediatrics, personalized medicine, preventative medicine, primary care, rehabilitation, sinus, spinal care, urgent care, weight loss, wellness and women’s health.
Arrayit recently established a nationwide sales network of 1,700 sales professionals to sell and distribute the company’s finger stick microarray tests to medical clinics and retail chains, completed allergy pilot testing with one the nation’s largest chains of retail stores, met with top officials at the United States Food and Drug Administration (FDA) to discuss FDA approval of a major product line, and reported the sale of clinical instrumentation to the FDA. Arrayit microarray tests conveniently use a few drops of patient blood collected on a blood card to assist doctors in identifying and treating food intolerance, allergy and asthma, and pipeline indications for more serious conditions such as ovarian cancer and Parkinson’s Disease. Doctors can use allergy test results as quantitative tools to inform decisions regarding allergy medicines, immunotherapy, food elimination and lifestyle changes.
https://www.marketwatch.com/press-release/arrayit-corporation-signs-allergy-testing-contracts-with-a-nationwide-consortium-of-medical-clinics-2018-07-30?siteid=bigcharts&dist=bigcharts
8-7-18: Arrayit senior management submits $5,000,000 strategic investment proposal to a companion diagnostics and therapeutics leader headquartered in the San Francisco Bay Area USA and commercializing medicines for the massive $45 billion neurodegenerative market
https://twitter.com/arrayit/status/1026860386782339072
8-13-18: August 13, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, has been approved for in-store allergy testing promotions by a major United States retailer. Arrayit sales and marketing experts will conduct allergy test promotions in-store, and medical professionals at in-store clinics will collect finger stick blood specimens. Two thousand retail locations nationwide averaging 3,000 customer visits per store per day would give Arrayit access to 6 million retail customers daily, creating the potential for exponential sales growth. This promotional campaign required rigorous vetting and high-level corporate approval by the retailer, which reports revenues exceeding $50 billion annually.
https://www.marketwatch.com/press-release/arrayit-corporation-receives-approval-for-in-store-promotions-by-a-major-retail-chain-2018-08-13?siteid=bigcharts&dist=bigcharts
8-27-18: August 27, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces allergy testing partnerships with multiple providers of allergen immunotherapy products including sub-cutaneous, sublingual, and oral allergy medicines designed to treat patients of allergy and asthma. Allergen immunotherapy, a time-tested clinical approach, can reduce or eliminate allergy and asthma symptoms by lowering the levels of specific cellular proteins known as immunoglobulin E (IgE) molecules that activate the immune system and trigger immune responses. Through these partnerships, doctors prescribing Arrayit allergy tests gain access to a portfolio of safe, effective and convenient allergy medicines for their allergy and asthma patients, including custom immunotherapy products formulated upon review of quantitative allergy test results.
https://www.marketwatch.com/press-release/arrayit-corporation-announces-allergy-testing-partnerships-with-major-allergy-therapeutics-providers-2018-08-27-51843016?siteid=bigcharts&dist=bigcharts
9-10-18: September 10, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that Arrayit's proprietary finger stick allergy microarray test has been approved for direct Medicare billing by the Centers for Medicare and Medicaid Services (CMS). The Medicare national health insurance program provides health insurance to more than 55 million Americans annually, including 46 million seniors and 9 million younger people. CMS projects a 2018 Medicare budget of approximately $705,000,000,000 ($705 billion dollars), representing about 17% of total federal spending.
https://www.marketwatch.com/press-release/arrayit-corporation-approved-for-direct-medicare-billing-by-the-centers-for-medicare-and-medicaid-services-2018-09-10?siteid=bigcharts&dist=bigcharts
9-24-18: Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports the shipment of clinical instrumentation and quantification software to the United States Food and Drug Administration (FDA). Arrayit uses the same instrumentation and software to test for allergy and food intolerance as well as pipeline indications for ovarian cancer and Parkinson's Disease (PD). Testing is performed in the company's Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the California Department of Public Health (CDPH) and the Center for Medicare and Medicaid Services (CMS).
https://www.marketwatch.com/press-release/arrayit-corporation-ships-clinical-instrumentation-and-software-to-the-united-states-food-and-drug-administration-2018-09-24?siteid=bigcharts&dist=bigcharts
10-8-18: Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports that its clinical team aced three consecutive rounds of blinded-specimen Proficiency Testing (PT) with the College of American Pathologists (CAP). The SC-2017, SA-2018 and SB-2018 triannual CAP Diagnostic Immunology Surveys require highly quantitative measurements of immunoglobulin E (IgE), the antibody molecules measured by the company's finger stick allergy microarray tests. Arrayit's highly accurate PT performance showcases the robustness of the company's proprietary allergy testing platform and reagents, which are increasingly being leveraged by doctors as a tool to diagnose and treat allergy and asthma.
https://www.marketwatch.com/press-release/arrayit-corporation-aces-three-consecutive-rounds-of-proficiency-testing-with-the-college-of-american-pathologists-2018-10-08?siteid=bigcharts&dist=bigcharts
10-22-18: Published: Oct 22, 2018 5:30 a.m. ET
Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, launches a fully automated allergy testing portal for doctors and clinics to streamline and accelerate the allergy testing and treatment process. The Patient Data Solutions (PDS) allergy-testing suite is secure and fully compliant with Health Insurance Portability and Accountability Act (HIPAA) requirements to ensure the privacy of patient health records. The new PDS portal allows doctors to order allergy blood card collection kits, request express mail shipping labels, download allergy test results, and order immunotherapy products from our independent allergy therapeutics partners. The PDS portal, which is free of charge to doctors and clinics, offers continuous, real-time technical assistance to ensure a positive on-line experience.
https://www.marketwatch.com/press-release/arrayit-corporation-launches-patient-data-solutions-allergy-testing-portal-for-doctors-and-clinics-2018-10-22?siteid=bigcharts&dist=bigcharts
10-31-18: Arrayit provides an update to shareholders. We are currently is a quiet period regarding our financials. Our next financial announcement will be the filing of our 10-K and 10-Q forms through 2018. Thanks everyone for your continued support and patience! http://arrayit.com/index.html
https://twitter.com/arrayit/status/1057654833040113665
11-5-18: Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces expansion of its proprietary finger stick microarray allergy testing platform to a growing number of major market brands. Highly automated Arrayit technology is inherently suited to leveraging multiple brands and their unique venues and relationships to reach a larger number of allergy patients more quickly. Each brand serving major retail chains, large government agencies, medical clinics and doctor offices receive the same high-level testing support and treatment options through the company's Patient Data Solutions (PDS) on-line allergy testing portal and therapeutics affiliates.
Report TOS
Our next pick is NXEM see the link to some good DD .
http://ownthefloat.com/index.php/2018/07/29/ntva-heres-why-i-invested-in-intiva-biopharma/
Followers
|
16
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
414
|
Created
|
07/17/16
|
Type
|
Free
|
Moderator Gold prospector | |||
Assistants PennyStock Alert DDStocks |
No one is responsible for your gains, or losses in the market except YOU. If you follow stocks, strategies discussed on PTC you may LOSE ALL YOUR MONEY. Please weigh the strategies discussed here carefully against what you are willing to risk.
Please do your own due diligence before buying, or selling ANY SECURITY in the open market. There are no guarantees.
PTC nor its club members are NOT Compensated for any current or past mentioned stocks in anyway. Investing in Penny Stocks has a high risk factor and may cause you to lose some or all of your investment.
Never invest in Penny Stocks with money you cannot afford to lose. Please invest wisely after performing your own Due Diligence.
Posts Today
|
0
|
Posts (Total)
|
414
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |